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dataset). The models were also tested in a clinical dataset including ordered 
response categories for four different treatments in psoriasis patients. Both fixed 
and random effects models were studied. Results: In the POA dataset, the PO 
fixed effects model had the lowest residual deviance (54.8 versus 58.9 for the ML 
model) and uncertainty of treatment effects (49% lower standard error (SE)). In the 
nPOA dataset, the predictions of the PO model were biased, and the ML model had 
the lowest residual deviance (52.7 versus 271.0 for the PO model). Visual inspection 
indicated a partial violation of the PO assumption in the psoriasis data. Analyses of 
the psoriasis data, showed that the PO fixed effects model had the lowest residual 
deviance (18.1 versus 20.9) and uncertainty (62% lower SE). However, PO model 
predictions were biased for treatment responses which violated the PO assump-
tion. ConClusions: Statistical selection of NMA models for ordered outcomes 
should be based on the PO assumption and deviance measures. If data satisfies the 
PO assumption, the PO model differentiated treatment effects better as a result of 
lower uncertainty. In terms of flexibility, the PO model can handle data from studies 
that use different cut-offs for response categories and the ML model can be applied 
to datasets violating the PO assumption.
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objeCtives: The aim of the study was to assess the effect of an immunotherapy 
for the treatment of advanced non–small-cell lung cancer (NSCLC). Methods: 
Data from a phase III, multicenter, randomized, open-label trial evaluating the 
efficacy of one EGF-based cancer vaccine (CIMAvaxEGF) as switch maintenance in 
patients with advanced NSCLC, were used. Survival analysis using Kaplan Meier 
estimates was performed. Weighted log-rank was conducted to assess the later 
effect of the immunotherapy. Additionally, a finite mixture model to the primary 
endpoint (Overall Survival, OS) was fitted. Weibull distribution was assumed for 
the overall survival and a mixture model consists of one, two or three components 
was fitted.. All analysis was conducted using the NLMIXED procedure in SAS. 
The Akaike Information Criterion (AIC) was used for model selection. Results: 
Intention-to-treat (ITT) analysis showed 1.44 months of OS benefit for vaccinated 
patients with confirmed delayed-separation phenomena (OS: Vaccine arm, 10.37 
months vs. Control arm, 8.93 months; p= 0.043). The mixture model with the best 
goodness to fit to the data consists of two components (AIC= 3097.7). The two 
mixture components represent short-term and long-term survival subpopula-
tions. The proportions of the subpopulations are estimated to be equal to 0.89 
and 0.11 respectively. The median OS was estimated to be equal to 9.59 and 60.32 
for short- and long- term survival populations, respectively. 23.26% and 76.74% 
from the patients who were classified into long-term survival subpopulation were 
from the control and vaccinated group, respectively. From them, 7 (70%) patients 
in the control group and 25 (75%) patients in the treated group were still alive at 
the end of the study. ConClusions: The results confirm that the vaccination 
with CIMAvaxEGF prolongs the survival of the advanced NSCLC patients. Mixture 
models allow assessing the efficacy/effectiveness of vaccines and biological prod-
ucts in the presence of heterogeneous populations.
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objeCtives: In the third party funder environment most analyses focus on ret-
rospective claims analyses; the aim of predictive modelling is to estimate future 
claims or current risk, based on the probability of a hospital event using historical 
data. Methods: A logistic regression approach is followed where the likelihood of 
a hospitalisation event is established and mapped to a cost estimate. The modelling 
process involved establishing a development and validation sample, identifying the 
predictor variables, building and lastly validating the sample. During the model 
building process the development and validation population consisted of 149 416 
and 47623 beneficiaries respectively; where the data was obtained from a third 
party funder consisting of 3 years of data. During the building process the depend-
ant variable (Y= Logg (odds)) takes on the value 1 or 0 depending on whether or not a 
hospital event occurred. To calculate the cost per beneficiary a weighted probability 
was multiplied by the average cost of a hospital authorisation. Beneficiaries were 
classified as high risk if log (odds) > = 0.7. Results: The final model is: Log (odds) 
= -0.11X1+0.00576X2+0.409X3+0.179X4+0.614X5 where X1-X5 denotes the predictor 
variables. X1 denotes an indicator variable for gender, X2 the predictor variable for 
age, X3 the HIV indicator variable, X4 the diabetes indicator variable and X5 the 
chronic indicator variable. The strongest predictors were the chronic indicator vari-
able and age. The validation process resulted in 79% of the beneficiaries being cor-
rectly classified and the cost estimation resulted in totals within 3-5% of the actual 
values. ConClusions: The proposed model predicts hospitalisation efficiently at 
a beneficiary level and can be implemented to monitor risk and the associated cost 
(hospital or total) for individuals, employer group or the third party funder. Third 
party risk management and cost estimation are other applications of the model.
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parameter, we also modeled the precision parameter using a regression structure. 
Regression coefficients and predictive accuracy from this model estimated using 
the Bayesian approach with vague priors were compared to those from a linear 
mixed effects model estimated classically. Results: Our results indicated that beta 
distribution fitted the SF-6D outcome better than normal distribution. Furthermore, 
compared to the linear mixed effects model, the mixed beta regression model was 
superior in terms of predictive model accuracy. We found that mortality risk had a 
significant effect on both mean and precision parameters: we observed lower mean 
HRQoL for higher mortality risk and higher variation of health utilities for higher 
mortality risk. ConClusions: Mixed beta regression offers a superior approach 
for modelling the HRQoL outcome longitudinally. Furthermore, such a model can 
be easily implemented using freely available Bayesian software.
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objeCtives: Parametric survival modeling (PSM) is often used in cost-effectiveness 
analyses of oncology treatments to aid in lifetime projections due to right censor-
ing of data. We sought to better understand the effect of sample sizes and data 
maturity (follow-up time) on PSM projections to aid in the design of clinical tri-
als and the interpretation of cost-effectiveness models. Methods: We modeled 
overall survival (OS) for advanced colorectal cancer patients treated with first-line 
chemotherapy and/or a biologic using SEER-Medicare data (2004-2010). Survival 
was estimated using Kaplan-Meier (KM) and PSM methods. From the full cohort, we 
randomly drew patients to match typical sample sizes from Phase II and III clinical 
trials (n= 50, 100, 200, and 400). Additionally, arbitrary data cutoffs were created 
to proxy clinical trial follow-up times (t= 3, 6, 9, 12, 24, and 36 months). Using PSM 
methods mean survival from the full cohort was compared with survival from the 
combinations of sample sizes and follow-up times. Results: Using the KM method, 
6% of patients were alive at the end of the follow-up period (6.5 years). Mean OS 
from the full cohort was estimated to be 21.9 months using the PSM method (best 
fit Weibull curve). OS estimates for the sample size and follow-up time combina-
tions ranged from 5.9-28.0 months. Minimum and maximum survival projections 
represented a 73% underestimation and 28% overestimation of survival compared 
with the full cohort projection, respectively. Projection accuracy was improved when 
t≥ 6 months and n≥ 200. ConClusions: Both sample size and data maturity have 
a profound effect on survival projections. Care should be taken when interpreting 
projections in cost-effectiveness models, especially when sample size is low and 
follow-up time short. In addition to power calculations, clinical trial design should 
account for these issues. Additional analyses in other cancer types may provide 
further guidance for optimum trial design.
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objeCtives: Approximately 65% of patients diagnosed with hypertension are 
not well controlled and two third of patients need to be treated by two or more 
drugs for achieving target blood pressure. The aim of this study was to describe 
antihypertensive treatment patterns in real life settings by using Markov chain 
model. Methods: Data concerning prescriptions of patients with diagnosed hyper-
tension were obtained from a large primary care survey conducted in 2012 using 
CSD Longitudinal Patient Database. Patients selected were treated with sartans, 
prescribed alone or in combination with amlodipine and/or hydrochlorothiazide 
(HCT), either in free associations or in fixed combinations. A Markov chain model 
M1 with 4-states (A: single sartan, B: sartan+ amlodipine, C: sartan + HCT, D: sar-
tan + amlodipine + HCT) was proposed to model transitions from one treatment 
to another over time. A second chain, M2, with 6 states was also studied, in which 
dual-therapies were divided into two states depending on whether the combination 
was free or fixed. Age and sex were included as covariates. R packages and MSM 
DIAGRAM were used. Results: 11,976 patients were selected, 49% were men, aged 
69 years on average (SD = 11), suffering from hypertension for 7 years on average, 
35% had diabetes, 5% renal failure and 31% a previous cardiovascular event. At the 
time of selection, the distribution between the states was as follows: A: N = 5187 
(43.3%), B: N = 1060 (8.9%), C: N = 5120 (42.8%), D: N = 609 (5%). At the end of one 
year, > 93% of patients had remained in the same state of M1. The M2 model showed 
substantial transitions from free to fixed associations. Age and sex did not change 
the coefficients. ConClusions: The Markov chains used to visually describe the 
evolution of treatment regimens are useful for analyzing large longitudinal data-
bases of prescriptions.
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objeCtives: Network meta-analysis (NMA) techniques have been developed to 
study relative treatment effects for several outcome types (e.g. time-to-event out-
comes). No literature exists comparing models of NMA for ordered categorical data, 
though models are available with different characteristics. This study compared 
the proportional odds (PO) and multinomial logistic (ML) model for NMA in ordered 
categorical datasets based on model fit and qualitative characteristics. Methods: 
To contrast model performance, two extreme datasets were simulated, one which 
exactly satisfied the PO assumption (POA dataset), and one which did not (nPOA 
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ing DIF were related to the dimension “precise movement” and were detected in 
the Spain-Italy comparison (Δ R2 [left hand] = 0.2165, Δ R2 [right hand] = 0.1618) 
and in the Spain-France comparison (Δ R2 [left hand] = 0.1571, Δ R2 [right hand] 
= 0.1578). ConClusions: Globally, these data support the H-CSRI cross-cultural 
validity. Further analyses should be conducted to confirm if those particular items 
need to be revised in the Spanish version.
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objeCtives: The Occupational Contact Dermatitis Disease Severity Index (ODDI) 
was designed in Australia to measure severity and functional disability in patients 
with occupational contact dermatitis (OCD) of the hands. The psychometric prop-
erties of the German version of the ODDI are unclear. Our objective was to investi-
gate the validity and reliability of the German ODDI version. Methods: The ODDI 
was translated and linguistically validated into German for Germany, following 
industry standard procedures of concept definition, dual forward translation, back 
translation and reconciliation, and clinician review. Once the German version was 
available, data was drawn from the baseline assessment (T0) and first follow-up 
(T1) of the German chronic hand eczema (CHE) registry (carpe). Spearman cor-
relations of the ODDI with reference measures were computed to assess valid-
ity. Cronbach’s alpha was calculated as a measure of internal consistency and the 
intraclass correlation coefficient (ICC) to assess retest-reliability. Smallest real dif-
ference (SRD) and minimal clinical important difference (MCID) were calculated 
to assess sensitivity to change. Physician Global Assessment (PGA) was used as an 
anchor for the MCID. Results: 422 patients (54.5% female, mean age: 45.1 years) 
were included for analysis. Cronbach’s α was found to be 0.73. The ICC was 0.79. 
Correlations of the ODDI total and the Dermatology Life Quality Index (rho= 0.36) 
as well as the PGA (rho= 0.48) and patient-assessed disease severity (rho= 0.40) 
were of moderate strength. The MCID (1.29) was found to be smaller than the SRD 
(1.87). ConClusions: The German ODDI version is reliable and valid to measure 
functional impairment and disease severity in patients suffering from OCD. The 
MCID falls within the range of measurement error and should not be used.
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objeCtives: To evaluate the predictive performance of a previously published 
mapping algorithm for converting the prostate cancer specific instrument FACT-P 
(Functional Assessment of Cancer Therapy–Prostate) to EQ-5D utility values (UK tariff) 
on a sample with a different disease stage than the one on which the model was 
generated [Skaltsa et. al. ViH 2014]. Methods: We applied a previously developed 
algorithm to the data obtained from a randomized, double-blind, placebo-controlled 
phase 3 trial in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. 
The trial collected EQ-5D and FACT-P data at baseline and until treatment discon-
tinuation. The mapping model was developed on mCRPC patients in a post-chemo 
setting, included the FACT-P subscale scores and baseline variables and used sepa-
rate algorithms for patients with good and poor health defined as a FACT-P score 
exceeding or not 76. Model performance was assessed by mean absolute error (MAE) 
and root mean squared error (RMSE). Results: The testing dataset contained 1,669 
patients with baseline and ≥ 1 post-baseline scores. The average baseline EQ-5D 
utility and FACT-P total score were 0.844 and 119.5 respectively. Percentage of per-
fect health was 37% across all visits (ceiling effect). The average (across all visits) 
observed and predicted EQ-5D utility index value was 0.823 and 0.842, respectively. 
The model yields accurate predictions (MAE= 0.107; RMSE= 0.150) comparable to 
the ones obtained on the development sample (MAE= 0.117; RMSE= 0.162). The 
model predicts well for milder health states, but overpredicts for the more severe 
ones (EQ-5D utility≤ 0.5: MAE= 0.436, RMSE= 0.258; EQ-5D utility > 0.5: MAE= 0.096, 
RMSE= 0.125). ConClusions: Although external validation is recommended using 
similar samples, our findings show that the algorithm developed in the post-chemo 
setting performed well in a pre-chemo setting in mCRPC patients, although over-
predicts for severe states. This model seems suitable for predicting utility values for 
economic evaluation when a preference-based measure is absent in chemo-naïve 
mCRPC populations.
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objeCtives: In economic evaluations in oncology, survival data is typically extrap-
olated without taking into account prognostic factors. If individual level trial data 
are available, patient and disease characteristics observed at baseline are consid-
ered. However, survival models typically disregard information that are not known 
at baseline, e.g. response to treatment, but that may be valuable for the prognosis 
of patients and hence for decision making. In this study we present a parametric 
survival model that included response to treatment over time. Methods: Data 
from 99 patients with late-stage soft tissue sarcoma from a clinical trial was used. 
Survival information and the percentage change in the sum of the longest diam-
eters of target lesions (i.e. the basis for response evaluation) measured repeatedly 
during follow-up were utilized. A joint model was estimated linking a random 
effects sub-model for the change of tumor size with a Weibull sub-model for the 
survival outcome. The association between change of tumor size over time and 
overall survival was assessed. Several different functional forms were explored 
to model the tumor size data and the best fitting model was selected. Results: 
The median follow-up time in the trial was 1.6 years; 63 patients died. On aver-
age, 4.8 measurements on tumor size were available per patient. A flexible cubic 
B-spline sub-model provided the repeatedly measured tumor size change data the 
best model fit. The association between tumor growth and overall survival was 
marginally statistically significant with a P value of less than 0.10. ConClusions: 
The presented joint model demonstrated that response to treatment over time 
may be important to consider when building survival models for health economic 
evaluations in oncology. The model explicitly incorporated the heterogeneity of 
patients not observed at baseline providing a clinically relevant survival model. 
Individual survival predictions can be prepared using patient-specific history of 
tumor growth.
RESEaRch On MEthOdS – Patient-Reported Outcomes Studies
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objeCtives: The Huntington Quality of Life Instrument (H-QoL-I) is the first self-
reported specific instrument developed to assess the health-related QoL (HRQoL) 
of patients with Huntington’s disease (HD). It includes three subscales: motor 
(4 Likert-type items), psychology (4 Likert-type items) and socializing (3 Likert-
type items). The aim of the study was to assess whether patients from different 
countries respond differently to the H-QoL-I instrument. Methods: Data were 
from the European study of HD burden (EURO-HDB) survey and included data 
across 6 countries: France, Germany, Italy, Spain, Poland and the USA. The Differential 
Item Functioning (DIF) method was adopted to examine whether patients from dif-
ferent countries with the same characteristics had different probability of giving 
a certain response on H-QoL-I. An item was considered as displaying a DIF if the 
p-value associated with the two-degree-of-freedom Chi-squared test comparing the 
two ordinal logistic regressions (with/without country effect and an interaction term 
between the total rest score and country) was lower than 0.01 and the Zumbo-Thomas 
effect size was higher than 0.130. Zumbo-Thomas effect size measure and associated 
p-value were calculated for each item and for all pairs of countries (i.e. 15 combina-
tions). Results: The study included 633 patients (176 French, 124 Italian, 44 German, 
60 Polish, 59 Spanish and 170 American). No DIF was detected across all combinations 
of countries for all items. Sixteen pairwise Zumbo-Thomas effect size measures refer-
ring to 7 items were found significant but were lower than 0.130. ConClusions: This 
study did not detect any variation across the studied countries in the assessment of 
HRQoL of HD patients using the H-QoL-I instrument. These results support the cross-
cultural validity of the H-QoL-I.
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objeCtives: The H-CSRI is the first clinimetric self-reported instrument for patients 
with Huntington’s disease (HD). It includes three subscales: motor (13 Likert-type 
items in 4 dimensions), functional (7 Yes/No questions) and behavioural (13 Likert-
type items in 4 dimensions). The aim of the study was to assess whether patients 
from different countries respond differently to H-CSRI. Methods: Data were from 
the European study of HD burden (EURO-HDB) survey and included data across 6 
countries: France, Germany, Italy, Spain, Poland and the USA. The Differential Item 
Functioning (DIF) method was adopted to examine whether patients from different 
countries with the same characteristics had different probability of giving a certain 
response on H-CSRI. An item was considered as displaying a DIF if the p-value 
associated with the two-degree-of-freedom Chi-squared test comparing the two 
ordinal logistic regressions (with/without country effect and an interaction term 
between the total rest score and country) was lower than 0.01 and the Zumbo-
Thomas effect size was higher than 0.130. Zumbo-Thomas effect size measure and 
associated p-value were calculated for each item and for all pairs of countries (i.e. 
15 combinations). Results: The study included 633 patients (176 French, 124 
Italian, 44 German, 60 Polish, 59 Spanish and 170 American). Almost all the 
items (24 of 26) didn’t show any cross/cultural difference. The two items show-
